journal article·2013-12-11

Facile Preparation of Paclitaxel Loaded Silk Fibroin Nanoparticles for Enhanced Antitumor Efficacy by Locoregional Drug Delivery

Puyuan Wu, Qin Liu, Rutian Li, Jing Wang, Xu Zhen, Guofeng Yue, Huiyu Wang, Fangbo Cui, Fenglei Wu, Mi Yang, Xiaoping Qian, Lixia Yu, Xiqun Jiang, Baorui Liu

Publisher page

Abstract

Non-toxic, safe materials and preparation methods are among the most important factors when designing nanoparticles (NPs) for future clinical application. Here we report a novel and facile method encapsulating anticancer drug paclitaxel (PTX) into silk fibroin (SF), a biocompatible and biodegradable natural polymer, without adding any toxic organic solvents, surfactants or other toxic agents. The paclitaxel loaded silk fibroin nanoparticles (PTX-SF-NPs) with a diameter of 130 nm were formed in an aqueous solution at room temperature by self-assembling of SF protein, which demonstrated mainly silk I conformation in the NPs. In cellular uptake experiments, coumarin-6 loaded SF NPs were taken up efficiently by two human gastric cancer cell lines BGC-823 and SGC-7901. In vitro cytotoxicity studies demonstrated that PTX kept its pharmacological activity when incorporating into PTX-SF-NPs, while SF showed no cytotoxicity to cells. The in vivo antitumor effects of PTX-SF-NPs were evaluated on gastric cancer nude mice exnograft model. We found that locoregional delivery of PTX-SF-NPs demonstrated superior antitumor efficacy by delaying tumor growth and reducing tumor weights compared with systemic administration. Furthermore, the organs of mice in NP treated groups didn't show obvious toxicity, indicating the in vivo safety of SF NPs. These results suggest that SF NPs are promising drug delivery carriers, and locoregional delivery of SF NPs could be a potential future clinical cancer treatment regimen.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Silk-based biomaterials and applications · Protease and Inhibitor Mechanisms · Phytochemical compounds biological activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, 321 Zhongshan Road, Nanjing 210008, China

Laboratory of Mesoscopic Chemistry and Department of Polymer Science, Engineering College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, China

Nanjing Medical University, 140 Hanzhong Rd, Nanjing 210029, China

The Comprehensive Cancer Center of Drum Tower Hospital, Nanjing Medical University, 321 Zhongshan Rd, Nanjing 210008, China

References (34)

Show source-provided references
1. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
2. Petros R. A. · Nat. Rev. Drug Discovery · 2010 · 9 · 61510.1038/nrd2591 ↗
3. Lin Q. · Biomaterials · 2013 · 34 · 719110.1016/j.biomaterials.2013.06.004 ↗
4. Lewinski N. · Small · 2008 · 4 · 2610.1002/smll.200700595 ↗
5. Ishida T. · J. Controlled Release · 2005 · 105 · 30510.1016/j.jconrel.2005.04.003 ↗
6. Vepari C. · Prog. Polym. Sci. · 2007 · 32 · 99110.1016/j.progpolymsci.2007.05.013 ↗
7. Altman G. H. · Biomaterials · 2003 · 24 · 40110.1016/S0142-9612(02)00353-8 ↗
8. Omenetto F. G. · Science · 2010 · 329 · 52810.1126/science.1188936 ↗
9. Panilaitis B. · Biomaterials · 2003 · 24 · 307910.1016/S0142-9612(03)00158-3 ↗
10. Wenk E. · J. Controlled Release · 2011 · 150 · 12810.1016/j.jconrel.2010.11.007 ↗
11. Altman G. H. · Biomaterials · 2002 · 23 · 413110.1016/S0142-9612(02)00156-4 ↗
12. Meinel L. · Biomaterials · 2005 · 26 · 14710.1016/j.biomaterials.2004.02.047 ↗
13. Wang X. · Biomaterials · 2010 · 31 · 102510.1016/j.biomaterials.2009.11.002 ↗
14. Lammel A. S. · Biomaterials · 2010 · 31 · 458310.1016/j.biomaterials.2010.02.024 ↗
15. Cao Z. B. · Soft Matter · 2007 · 3 · 91010.1039/b703139d ↗
16. Chen M. · J. Biomed. Mater. Res., Part A · 2012 · 100 · 20310.1002/jbm.a.33265 ↗
17. Shi P. · Int. J. Pharm. · 2011 · 420 · 28210.1016/j.ijpharm.2011.08.051 ↗
18. Bessa P. C. · Tissue Eng., Part C · 2010 · 16 · 93710.1089/ten.tec.2009.0486 ↗
19. Zhang Y. Q. · J. Nanopart. Res. · 2007 · 9 · 88510.1007/s11051-006-9162-x ↗
20. Zhang Y. Q. · Soft Matter · 2011 · 7 · 972810.1039/c0sm01332c ↗
21. Zhu L. · J. Agric. Food Chem. · 2011 · 59 · 1029810.1021/jf202036v ↗
22. Kundu J. · Int. J. Pharm. · 2010 · 388 · 24210.1016/j.ijpharm.2009.12.052 ↗
23. Wolinsky J. B. · J. Controlled Release · 2012 · 159 · 1410.1016/j.jconrel.2011.11.031 ↗
24. Hartgrink H. H. · Lancet · 2009 · 374 · 47710.1016/S0140-6736(09)60617-6 ↗
25. Sakamoto J. · Gastric Cancer · 2009 · 12 · 6910.1007/s10120-009-0505-z ↗
26. Weiss R. B. · J. Clin. Oncol. · 1990 · 8 · 126310.1200/JCO.1990.8.7.1263 ↗
27. Gelderblom H. · Eur. J. Cancer · 2001 · 37 · 159010.1016/S0959-8049(01)00171-X ↗
28. Rockwood D. N. · Nat. Protoc. · 2011 · 6 · 161210.1038/nprot.2011.379 ↗
29. Laemmli U. K. · Nature · 1970 · 227 · 68010.1038/227680a0 ↗
30. Zhou C. Z. · Proteins: Struct., Funct., Genet. · 2001 · 44 · 11910.1002/prot.1078 ↗
31. Zhu Z. S. · J. Controlled Release · 2010 · 142 · 43810.1016/j.jconrel.2009.11.002 ↗
32. Li X. L. · Mol. Pharmaceutics · 2012 · 9 · 22210.1021/mp2002736 ↗
33. Chen H. T. · Proc. Natl. Acad. Sci. U. S. A. · 2008 · 105 · 659610.1073/pnas.0707046105 ↗
34. Gupta V. · Int. J. Nanomed. · 2009 · 4 · 11510.2147/IJN.S5581 ↗